Key facts
- This page summarizes Daniel T. Scavilla's Form 4 filing for GLOBUS MEDICAL INC (GMED).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Nov 2024, 16:29.
Daniel T. Scavilla - 21 Nov 2024 Form 4 Insider Report for GLOBUS MEDICAL INC (GMED)
- Reporting relationship
- President, CEO, Director
- Issuer ticker
- GMED
- Reported as of
- 21 Nov 2024
- Net transaction value
- -$5,375,100
- SEC form
- 4
- Accepted by SEC
- 25 Nov 2024, 16:29:07 UTC
- Prior SEC filing
- 08 Nov 2024
- Next SEC filing
- 28 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kelly G. Huller, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel T. Scavilla filed Form 4 for GLOBUS MEDICAL INC (GMED) on 25 Nov 2024.
Change
- Previous filing in this sequence was filed on 08 Nov 2024.
- Current net transaction value: -$5,375,100.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GMED
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $2,188,500
- Shares
- +50,000
- Change %
- Price
- $43.77
- Shares after
- 50,000
- Date
- 21 Nov 2024
- Ownership
- Direct
GMED
transaction
Class A Common Stock
Options Exercise
- Transaction value
- $3,486,400
- Shares
- +80,000
- Change %
- +160%
- Price
- $43.58
- Shares after
- 130,000
- Date
- 21 Nov 2024
- Ownership
- Direct
GMED
transaction
Class A Common Stock
Sale
- Transaction value
- $11,050,000
- Shares
- -130,000
- Change %
- -100%
- Price
- $85.00
- Shares after
- 0
- Date
- 21 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GMED
transaction
Derivative
Stock Option (Right to Buy Class A Common Stock)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 50,000
- Exercise price
- $43.77
- Footnotes
- F2
GMED
transaction
Derivative
Stock Option (Right to Buy Class A Common Stock)
Options Exercise
- Transaction value
- $0
- Shares
- -80,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Nov 2024
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 80,000
- Exercise price
- $43.58
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
This sale was effected pursuant to a Rule 10b5-1 trading plan dated June 7, 2024 executed by the reporting person.
Footnote F2
These options were granted on January 22, 2018 and are fully vested.
Footnote F3
These options were granted on January 22, 2019 and are fully vested.